ChromoTek’s fluorescent two hybrid (F2H®) technology enables screening and validation of compounds in living cells
more
Push For Smart Industry: ChromoTek wins category "Biotechnology" and the overall first prize from 1200 participating companies.
moreVisit us at the annual meeting of the American Association for Cancer Research, booth 1038!
moreChromoTek's Chromobody® Technology for High Content drug profiling licensed to Bayer
moreReagents for your research

GFP-Booster / RFP-Booster to enhance, stabilize and
reactivate your fluorescent proteins

High quality monoclonal antibodies for your research.
Download "GFP-Trap® vs. Antibodies"
Assays for compound screening/ drug development

Our novel Camelidae antibody format to visualize endogenous
cellular proteins in live cells

Reversible protein-protein interaction assay for direct intracellular
analysis and screening in live cells



